ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Austin, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Skin Diseases
Food Hypersensitivity
Hypersensitivity
Psoriasis
Allergic Rhinitis

Eczema trials near Austin, TX, USA:

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema...

Active, not recruiting
Hand Eczema
Drug: Ruxolitinib cream
Drug: Vehicle

Phase 2

Incyte
Incyte

Pflugerville, Texas, United States and 35 other locations

The goal of this study is to determine the safety and effects of ENS-002, a live biotherapeutic product (LBP) consisting of commensal, clonal, non-pa...

Enrolling
Atopic Dermatitis Eczema
Atopic Dermatitis
Biological: ENS-002

Phase 1

Concerto Biosciences

Austin, Texas, United States

This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.

Enrolling
Atopic Dermatitis
Drug: ATI-2138

Phase 2

Aclaris Therapeutics
Aclaris Therapeutics

Austin, Texas, United States and 4 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Phase 3

AbbVie
AbbVie

Austin, Texas, United States of America and 179 other locations

This is a Phase 2, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S....

Not yet enrolling
Atopic Dermatitis
Drug: Placebo (Vehicle) Topical Gel
Drug: Fluocinonide Ointment

Phase 2

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)

Austin, Texas, United States and 9 other locations

/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

Phase 3

Amgen
Amgen

Austin, Texas, United States and 234 other locations

This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK10...

Enrolling
Dermatitis, Atopic
Drug: GSK1070806
Drug: Placebo

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Austin, Texas, United States and 95 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Pflugerville, Texas, United States of America and 558 other locations

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Lilly
Lilly

Pflugerville, Texas, United States of America and 320 other locations

Locations recently updated

assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult pa...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A

Phase 3

AbbVie
AbbVie

Austin, Texas, United States of America and 61 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems